A 20-year real-world study on drug survival and predictive factors for infliximab discontinuation in Behçet’s syndrome
IFX showed good safety profile and excellent clinical response in this real-world BS cohort, with a drug survival of 45% within a median treatment duration of 37 months.
Authors
- Marta Mosca (ORCID: https://orcid.org/0000-0001-5937-4574)
- Federica Di Cianni (ORCID: https://orcid.org/0000-0001-6634-6790)
- Diana Marinello
- Maria Laura Manca (ORCID: https://orcid.org/0000-0002-9274-2313)
- Antonello Sulis
- Rosaria Talarico
Institutions
- University of Siena (IT)
- University of Pisa (IT)
- Azienda Ospedaliera Universitaria Pisana (IT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-08
- DOI
- https://doi.org/10.3389/fimmu.2025.1726690
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 0.00